Nintedanib
Radiation Pneumonitis
Second Hospital of Shanxi Medical UniversitySmall moleculeActive
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Radiation Pneumonitis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Babaodan Fifth Affiliated Hospital, Sun Yat-Sen University | Phase 2 | CCC |
hl301 Hanlim Pharm. Co., Ltd. | Phase 2 | CCC |
Budesonide Instituto Nacional de Cancerologia de Mexico | Phase 2 | CCC |
FAPi-46 University of California, Los Angeles | Early Phase 1 | C |
Same molecule, other indications
Nintedanib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →